SCHEMBL6036152

SCHEMBL6036152

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCCOc1cccc(CC(=O)O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4B P0C869 2/20 0.43
PPARA Q07869 5/20 0.42
PPARD Q03181 4/20 0.42
PPARG P37231 4/20 0.42
PTPN11 Q06124 1/20 0.39
DGAT1 O75907 1/20 0.38
LTB4R Q15722 1/20 0.37
IDE P14735 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NR1H2 P55055 3/20 0.37
NR1H3 Q13133 3/20 0.37
RXRA P19793 2/20 0.37
MEN1 O00255 1/20 0.37
NR1I2 O75469 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
VHL P40337 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035959 0.98 PLA2G4B (0.42) PLA2G4BPPARAPPARDPPARGPTPN11
SCHEMBL6036203 0.91 NR1H2 (0.43) PLA2G4BPPARAPPARDPPARGDGAT1
SCHEMBL6035872 0.90 PPARA (0.41) PPARAPPARDPPARGLTB4RIDE
SCHEMBL6034663 0.90 PPARG (0.44) PLA2G4BPPARAPPARDPPARGLTB4R
SCHEMBL6035712 0.88 PPARG (0.44) PLA2G4BPPARAPPARDPPARGSMN1; SMN2
SCHEMBL6034637 0.87 GCGR (0.38) PPARAPPARDPPARGSMN1; SMN2NR1H2
SCHEMBL6035465 0.87 PLA2G4B (0.39) PLA2G4BPPARAPPARDPPARGDGAT1
SCHEMBL6035650 0.87 PLA2G4B (0.39) PLA2G4BPPARAPPARDPPARGDGAT1
SCHEMBL6035583 0.86 PLA2G4B (0.40) PLA2G4BPPARAPPARDPPARGPTPN11
SCHEMBL6035112 0.86 PPARD (0.42) PPARAPPARDPPARGNR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 PLA2G4B 4180/4885PPARA 1717/4885PPARD 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.